BioRN Leads InnoLife Consortium to Success in the Competition Healthy Living and Active Ageing of the EIT
BioRN is a member of the consortium InnoLife, which has won the call for the Knowledge and Innovation Community (KIC) Healthy Living and Active Ageing (EIT Health) of the European Institute for Innovation and Technology (EIT). With a grant volume of up to €700 million and a total project volume of more than €2 billion, this is one of the largest publicly funded initiatives in the health sector worldwide.
Among the 50 core partners and additional 90 associate organisations from nine EU countries are, among others, Roche Diagnostics in Mannheim, AbbVie in Ludwigshafen and the University of Heidelberg as representatives of the BioRN cluster as well as major institutions and companies from the BioRN partner regions Cambridge in the United Kingdom and Leuven in Belgium (Health Axis Europe Alliance). In the next 7 years the consortium partners will cooperate as a Knowledge and Innovation Community (KIC) with the aim of delivering innovative products, services and concepts that will improve quality of life and contribute to the sustainability of healthcare across Europe. During the application phase the German partners of the consortium, including the BioRN cluster in Heidelberg as well as the top regions BioM in Munich, Medical Valley in Erlangen and BIO.NRW with its locations in Cologne and Aachen, had already agreed that the EIT Health projects would be coordinated from Heidelberg.
BioRN managing director Dr Christian Tidona made the following statement on winning the KIC call: “The successful initiation of this worldwide unique large-scale project is the direct result of the investment of the German Federal Government, the State of Baden-Württemberg and the regional partners in our BioRN leading-edge cluster. This opportunity for internationalization and active participation from major local institutions and companies in the health sector will sustainably strengthen our Rhine-Neckar metropolitan region.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance